Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 35.66 -5.64% -2.13
SUPN closed down 5.64 percent on Friday, March 22, 2019, on 1.37 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical SUPN trend table...

Date Alert Name Type % Chg
Mar 22 50 DMA Resistance Bearish 0.00%
Mar 22 MACD Bearish Centerline Cross Bearish 0.00%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 20 DMA Resistance Bearish -5.64%
Mar 21 Fell Below 50 DMA Bearish -5.64%
Mar 21 Inside Day Range Contraction -5.64%
Mar 21 Oversold Stochastic Weakness -5.64%
Mar 20 20 DMA Resistance Bearish -6.26%
Mar 20 50 DMA Support Bullish -6.26%

Older signals for SUPN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Health Pharmaceutical Pharmaceutical Industry Drug Discovery Clinical Trial Epilepsy Depression Design Of Experiments Attention Deficit Hyperactivity Disorder Clinical Research Clinical Trial Product Central Nervous System Diseases Treatment Of Central Nervous System Diseases Neurology Treatment Of Depression Treatment Of Epilepsy
Is SUPN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 61.25
52 Week Low 30.05
Average Volume 562,100
200-Day Moving Average 44.6264
50-Day Moving Average 37.8278
20-Day Moving Average 38.4305
10-Day Moving Average 37.932
Average True Range 1.4922
ADX 12.82
+DI 15.9368
-DI 25.456
Chandelier Exit (Long, 3 ATRs ) 38.5734
Chandelier Exit (Short, 3 ATRs ) 40.1066
Upper Bollinger Band 41.3553
Lower Bollinger Band 35.5057
Percent B (%b) 0.03
BandWidth 15.221244
MACD Line -0.1851
MACD Signal Line 0.082
MACD Histogram -0.2671
Fundamentals Value
Market Cap 1.81 Billion
Num Shares 50.7 Million
EPS 1.98
Price-to-Earnings (P/E) Ratio 18.01
Price-to-Sales 8.00
Price-to-Book 8.81
PEG Ratio 1.42
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.79
Resistance 3 (R3) 40.23 39.31 39.10
Resistance 2 (R2) 39.31 38.26 39.08 38.87
Resistance 1 (R1) 37.48 37.61 37.02 37.04 38.64
Pivot Point 36.56 36.56 36.33 36.33 36.56
Support 1 (S1) 34.73 35.51 34.27 34.29 32.68
Support 2 (S2) 33.81 34.86 33.58 32.45
Support 3 (S3) 31.98 33.81 32.22
Support 4 (S4) 31.54